Pharmacovigilance analysis of adverse event reports for aliskiren hemifumarate, a first-in-class direct renin inhibitor

BACKGROUND: The purpose of this study was to examine the postmarketing safety profile of aliskiren hemifumarate, a first-in-class direct renin inhibitor. METHODS: The US Adverse Event Reporting System (AERS) was utilized to conduct a retrospective pharmacovigilance analysis by applying the Multi-ite...

Descripción completa

Detalles Bibliográficos
Autor principal: Ali, Ayad K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3176166/
https://www.ncbi.nlm.nih.gov/pubmed/21941439
http://dx.doi.org/10.2147/TCRM.S23889

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3176166/
https://www.ncbi.nlm.nih.gov/pubmed/21941439
http://dx.doi.org/10.2147/TCRM.S23889

Ejemplares similares